Breaking NewsUK Cannabis Firm GW Pharmaceuticals Honoured By Her Majesty...

UK Cannabis Firm GW Pharmaceuticals Honoured By Her Majesty For Its Innovation

-

LEADING UK cannabis company GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in recognition of its ground-breaking work in creating the world’s first regulatory approved, prescription cannabis-based medicines.

Regarded as the highest official UK award for British business, the Queen’s Award for Enterprise is an annual award which recognises outstanding achievement in Innovation and is now in its 55th year. 

Formed in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines such a Sativex and Epidiolex, supporting tens of thousands of patients and families around the world. 

Supporting Patients

Most of its 1,100 staff are employed in the UK and over the years has invested over £1.3bn in the research, development and infrastructure needed to bring innovative medicines to patients. 

Dr Geoffrey Guy, Founder and Chairman said: “We are honoured to receive such a prestigious award for British businesses. When Dr Brian Whittle and I founded GW 23 years ago, our mission was to improve the lives of seriously ill patients by unlocking the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials in order to obtain regulatory approval for such medicines to benefit patients. 

“Today, I want to thank every employee, clinician, researcher, patient and caregiver for helping advance and achieve that mission.”

Earlier this year Irish firm Jazz Pharmaceuticals had a $7.2bn takeover bid for NASDAQ-listed GW accepted.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

1 COMMENT

Comments are closed.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you